argenx Phase 3 ADAPT OCULUS trial shows VYVGART improves ocular myasthenia gravis symptoms

• argenx outlined new VYVGART data already being presented at American Academy of Neurology meeting in Chicago on April 18-22, 2026, targeting broader use in myasthenia gravis and CIDP.
• Phase 3 ADAPT OCULUS results showed VYVGART improved ocular myasthenia gravis symptoms versus placebo, supporting planned US label-expansion filing.
• Phase 3 ADAPT SERON updates indicated VYVGART delivered rapid, repeatable benefit across harder-to-treat generalized MG subtypes, with FDA decision due May 10, 2026 under priority review.
• Post hoc ADHERE analysis suggested earlier first-line use of VYVGART Hytrulo in treatment-naïve CIDP, with most patients showing early clinical improvement.
• Pipeline focus shifted to CIDP competition with two Phase 3 empasiprubart studies, including a head-to-head trial versus IVIg and a placebo-controlled trial, with designs presented at AAN 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-045083), on April 20, 2026, and is solely responsible for the information contained therein.